Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis
Top Cited Papers
Open Access
- 11 July 2019
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 134 (2) , 147-159
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is an often-fatal disorder characterized by the overactivation of T cells and macrophages that excessively produce proinflammatory cytokines, including interferon-γ (IFN-γ). Previously, we reported that the JAK inhibitor ruxolitinib dampens T-cell activation and lessens inflammation in a model of HLH in which perforin-deficient (Prf1−/−) mice are infected with lymphocytic choriomeningitis virus (LCMV). Ruxolitinib inhibits signaling downstream of IFN-γ, as well as several other JAK-dependent cytokines. As a consequence, it remained unclear whether ruxolitinib was exerting its beneficial effects in HLH by inhibiting IFN-γ signaling or by targeting signaling initiated by other proinflammatory cytokines. To address this question, we compared the effects of ruxolitinib with those obtained using an IFN-γ–neutralizing antibody (αIFN-γ) in 2 murine HLH models. In both models, ruxolitinib and αIFN-γ reduced inflammation-associated anemia, indicating that ruxolitinib operates in an IFN-γ–dependent manner to reverse this HLH manifestation. In contrast, the number and activation status of T cells and neutrophils, as well as their infiltration into tissues, were significantly reduced following treatment with ruxolitinib, but they remained unchanged or were increased following treatment with αIFN-γ. Notably, despite discontinuation of ruxolitinib, LCMV-infected Prf1−/− mice exhibited enhanced survival compared with mice in which αIFN-γ was discontinued. This protective effect could be mimicked by transient treatment with αIFN-γ and a neutrophil-depleting antibody. Thus, ruxolitinib operates through IFN-γ–dependent and -independent mechanisms to dampen HLH by targeting the deleterious effects of T cells and neutrophils, with the latter representing an unappreciated and understudied cell type that contributes to HLH pathogenesis.Keywords
This publication has 57 references indexed in Scilit:
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative ColitisNew England Journal of Medicine, 2012
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- Making Sense of the Cytokine Storm: A Conceptual Framework for Understanding, Diagnosing, and Treating Hemophagocytic SyndromesPediatric Clinics of North America, 2012
- Repeated TLR9 stimulation results in macrophage activation syndrome–like disease in miceJournal of Clinical Investigation, 2011
- Hemophagocytosis causes a consumptive anemia of inflammationJournal of Experimental Medicine, 2011
- Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosisBlood, 2011
- Successful use of infliximab in macrophage activation syndrome with severe CNS involvementScandinavian Journal of Rheumatology, 2010
- Neutralization of IFNγ defeats haemophagocytosis in LCMV‐infected perforin‐ and Rab27a‐deficient miceEMBO Molecular Medicine, 2009
- Myelomonocytic cell recruitment causes fatal CNS vascular injury during acute viral meningitisNature, 2008
- Success with infliximab in treating refractory hemophagocytic lymphohistiocytosisAmerican Journal of Hematology, 2005